ABSTRACT
Objective Advances in genetics has led to a better understanding of both genetic and environmental contributions to psychiatric mental health disorders. But psychiatric genetics research is predominantly Eurocentric, and individuals of non-European ancestry continue to be significantly underrepresented in research studies. The objective of this study was to examine factors associated with genetic study participation in a schizophrenia sample.
Methods The study sample was extracted from the Clinical Antipsychotics Trial of Intervention Effectiveness (CATIE) schizophrenia study which enrolled patients with schizophrenia between the ages of 18-65 and incorporated an optional genetic sub-study. Using regression models, we examined sociodemographic and clinical factors that were independently associated with participation in the genetic sub-study.
Results The genetic sub-study had a lower proportion of Black (30% in genetic vs 40% in CATIE overall) and Other race (4% vs 6%) participants. Severe psychopathology symptoms (odds ratio [OR]=0.78, p=0.004) and better reasoning scores (OR = 1.16, p = 0.036) influenced the odds of genetic study participation. Compared to Black participants, White participants were significantly more likely to participate in the genetic sub-study (OR=1.43, p=0.009)
Conclusion Race and clinical variables significantly impact genetic study participation of individuals with schizophrenia. Future studies should examine the interactive effects of race and clinical variables for a nuanced understanding of how individuals diagnosed with severe psychiatric illnesses choose to participate in genetics studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Exempt approval by Duke IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data can be accessed with permission from NIH NDCT
